Free Trial
NASDAQ:TTNP

Titan Pharmaceuticals 8/14/2023 Earnings Report

Titan Pharmaceuticals logo
$3.90 -0.06 (-1.39%)
Closing price 08/8/2025 03:57 PM Eastern
Extended Trading
$3.90 +0.01 (+0.26%)
As of 08/8/2025 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Titan Pharmaceuticals EPS Results

Actual EPS
-$2.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Titan Pharmaceuticals Revenue Results

Actual Revenue
$0.08 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Titan Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Titan Pharmaceuticals' next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules.

Conference Call Resources

Titan Pharmaceuticals Earnings Headlines

A new rule goes live in July — and the banks are quietly crushing it
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
Titan Pharmaceuticals Inc (TTNP) - Investing.com
See More Titan Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Titan Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Titan Pharmaceuticals and other key companies, straight to your email.

About Titan Pharmaceuticals

Titan Pharmaceuticals (NASDAQ:TTNP), a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

View Titan Pharmaceuticals Profile

More Earnings Resources from MarketBeat